"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
| Descriptor ID |
D000978
|
| MeSH Number(s) |
D27.505.954.427.090.050
|
| Concept/Terms |
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
|
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in this website by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.
-
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020 04 01; 38(10):1019-1029.
-
Lipidomic Analysis of a-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell. 2019 03 07; 73(5):1001-1014.e8.
-
Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice. J Neurosci. 2014 Feb 19; 34(8):3090-4.
-
Deep brain stimulation for movement disorders: what counts in the end is the end result. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):474.
-
Anticholinergic responsive cyclic myoclonus. Mov Disord. 2013 Mar; 28(3):401-2.
-
Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Oct; 83(10):1015-7.
-
Serotonergic action on dorsal striatal function. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S129-31.
-
Preservation of function in Parkinson's disease: what's learning got to do with it? Brain Res. 2011 Nov 14; 1423:96-113.
-
Kleptomania treated with tolcapone, a catechol-O-methyl-transferase (COMT) inhibitor. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15; 35(1):295-6.
-
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):11-23.